Fenwick Represents CareDX in Pending Acquisition of Naveris

Fenwick is representing CareDx, Inc. (Nasdaq: CDNA), a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, in its pending acquisition of Naveris, a commercial stage precision oncology diagnostics company with a blood‑based monitoring solution for viral‑mediated cancers. More information can be obtained from CareDx’s announcement.

The Fenwick transaction team includes corporate partners Doug Cogen and Lynda Twomey and associates Rob O’Connor, Jing Liu and Bowen Xue; technology transactions partner Jake Handy and associate Shannon Coffey; executive compensation and employee benefits partner Jim Hauser and associates Christophe Delrieu and Christian Ingrassia; privacy and cybersecurity partner Ana Razmazma, counsel Sari Ratican and Melanie Jolson and associates Jason Raylesberg and Alyona Eidinger; antitrust and competition partner Steve Albertson, counsel Meredith Mommers and associate Susan Lee; and tax partner William Skinner and associate Kris Hatch.